Overall survival with camrelizumab plus famitinib versus camrelizumab alone and investigator's choice of chemotherapy for recurrent or metastatic cervical cancer
已完结10由 不可二二 发布于 2025/9/9 11:26:10
DOI:10.1016/j.ygyno.2024.07.040
作者:Xiaohua Wu , Lingfang Xia , Keqiang Zhang , Ying Tang , Guonan Zhang , Danbo Wang , Hanmei Lou , Naifu Liu , Hongping Zhang , Hongwei Chen , Ke Wang ,
文献类型:期刊论文
补充材料:只需要正文